Gedeon Richter’s Q1 Hit By Weak Ruble But Expects More M&A In Q2
Further Biotechnology And Women’s Health Expansion Expected In 2024
With two M&A deals expected to close in the second quarter, Gedeon Richter counts its wins and losses from a “solid” start to the year.
